Gain Therapeutics Inc (NASDAQ: GANX) has experienced a decline in its stock price by -14.04 compared to its previous closing price of 2.03. However, the company has seen a fall of -21.75% in its stock price over the last five trading days. globenewswire.com reported 2024-10-07 that GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson’s disease during a late-breaker poster session yesterday at the Society for Neuroscience (SfN) 2024 conference that is being held October 5-9 in Chicago, IL.
Is It Worth Investing in Gain Therapeutics Inc (NASDAQ: GANX) Right Now?
The 36-month beta value for GANX is at 0.26. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GANX is 24.23M, and currently, shorts hold a 2.72% of that float. The average trading volume for GANX on November 15, 2024 was 397.59K shares.
GANX’s Market Performance
GANX’s stock has seen a -21.75% decrease for the week, with a -40.24% drop in the past month and a 32.20% gain in the past quarter. The volatility ratio for the week is 12.68%, and the volatility levels for the past 30 days are at 12.21% for Gain Therapeutics Inc The simple moving average for the past 20 days is -26.43% for GANX’s stock, with a -29.71% simple moving average for the past 200 days.
Analysts’ Opinion of GANX
Many brokerage firms have already submitted their reports for GANX stocks, with Oppenheimer repeating the rating for GANX by listing it as a “Outperform.” The predicted price for GANX in the upcoming period, according to Oppenheimer is $8 based on the research report published on August 14, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see GANX reach a price target of $30. The rating they have provided for GANX stocks is “Outperform” according to the report published on April 12th, 2021.
BTIG Research gave a rating of “Buy” to GANX, setting the target price at $30 in the report published on April 12th of the previous year.
GANX Trading at -13.40% from the 50-Day Moving Average
After a stumble in the market that brought GANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.26% of loss for the given period.
Volatility was left at 12.21%, however, over the last 30 days, the volatility rate increased by 12.68%, as shares sank -37.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.83% upper at present.
During the last 5 trading sessions, GANX fell by -21.75%, which changed the moving average for the period of 200-days by -54.91% in comparison to the 20-day moving average, which settled at $2.37. In addition, Gain Therapeutics Inc saw -46.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GANX starting from Mack Gene, who purchase 14,400 shares at the price of $1.01 back on Aug 09 ’24. After this action, Mack Gene now owns 14,400 shares of Gain Therapeutics Inc, valued at $14,544 using the latest closing price.
Islam Khalid, the Executive Chairman of Gain Therapeutics Inc, purchase 50,000 shares at $1.00 during a trade that took place back on Aug 09 ’24, which means that Islam Khalid is holding 50,000 shares at $49,940 based on the most recent closing price.
Stock Fundamentals for GANX
Current profitability levels for the company are sitting at:
- -337.23 for the present operating margin
- -0.32 for the gross margin
The net margin for Gain Therapeutics Inc stands at -333.33. The total capital return value is set at -1.72. Equity return is now at value -188.83, with -115.33 for asset returns.
Based on Gain Therapeutics Inc (GANX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -39.0.
Currently, EBITDA for the company is -22.17 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 438.75. The receivables turnover for the company is 0.21for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.84.
Conclusion
In conclusion, Gain Therapeutics Inc (GANX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
